RESEARCH ARTICLE

Neuronal Nicotinic Acetylcholine Receptor Modulators Reduce Sugar Intake

Masroor Shariff[1], Maryka Quik[2], Joan Holgate[1], Michael Morgan[1], Omkar L. Patkar[1], Vincent Tam[3], Arnauld Belmer[1], Selena E. Bartlett[1] *

1 Institute of Health and Biomedical Innovation, Queensland University of Technology at Translational Research Institute, Brisbane, Australia, 2 Centre for Health Sciences, Bioscience Division, SRI International, Menlo Park, California, United States of America, 3 School of Psychology and Counselling, Queensland University of Technology, Brisbane, Australia

* selena.bartlett@qut.edu.au

Abstract

Excess sugar consumption has been shown to contribute directly to weight gain, thus contributing to the growing worldwide obesity epidemic. Interestingly, increased sugar consumption has been shown to repeatedly elevate dopamine levels in the nucleus accumbens (NAc), in the mesolimbic reward pathway of the brain similar to many drugs of abuse. We report that varenicline, an FDA-approved nicotinic acetylcholine receptor (nAChR) partial agonist that modulates dopamine in the mesolimbic reward pathway of the brain, significantly reduces sucrose consumption, especially in a long-term consumption paradigm. Similar results were observed with other nAChR drugs, namely mecamylamine and cytisine. Furthermore, we show that long-term sucrose consumption increases α4β2 * and decreases α6β2* nAChRs in the nucleus accumbens, a key brain region associated with reward. Taken together, our results suggest that nAChR drugs such as varenicline may represent a novel treatment strategy for reducing sugar consumption.

1. Introduction

Excess sugar consumption is implicated as one of the essential and underlying components of the current obesity epidemic, which is now a worldwide phenomenon [1, 2]. Indeed, binge sucrose drinking has been shown to repeatedly elevate dopamine levels in the nucleus accumbens (NAc) [3–6], a key feature of drugs of abuse [7–14]. Moreover, chronic intermittent sugar intake causes an increase in the expression of dopamine D1 receptors in the NAc, decrease in the expression of D2 receptors in the NAc and striatum [15–17] and also an increase in dopamine D3 receptor mRNA in the NAc and the caudate-putamen. Similar changes are noted in response to cocaine and morphine [18–24]. Furthermore, a decrease in enkephalin mRNA levels in the NAc[25] has been observed following intermittent sugar consumption [17], with similar observations in response to repeated injections of morphine [22, 23] or in cocaine-dependent human subjects [26]. Finally, during withdrawal from chronic sucrose exposure, rats show an imbalance in dopamine and acetylcholine,

i.e. dopamine levels decrease whilst acetylcholine levels increase [27], similar to changes observed with several drugs of abuse, including morphine, nicotine and alcohol [28–30]. This adds impetus to investigate the limbic system as a possible therapeutic target to reduce sugar consumption.

The limbic system is an interconnected collection of brain structures including the NAc and the ventral tegmental area (VTA) that encode emotional states such as anticipation of reward and motivation [31]. In relation to sugar consumption, the mesolimbic system has been shown to display an exaggerated incentive salience response to cues for sucrose [32–34]. Indeed, animal studies have shown that long-term consumption of palatable food can cause changes in the brain reward pathways, suggestive of an imbalance in the normal reward processing homeostasis [35, 36]. At the molecular level, Acetylcholine (ACh) from the cholinergic interneurons of the NAc binds to neuronal nicotinic acetylcholine receptors (nAChR), and modulates the release of dopamine (DA) and reinforced behaviours [37]. Interestingly, sucrose has been shown, albeit indirectly, to affect the release of DA in the NAc via nAChRs [38], suggesting that the nAChRs are a promising target for pharmacotherapy.

While numerous nAChR subtypes have been identified in the limbic system, including the NAc, identification of the nAChR subtype(s) involved in mediating and maintaining sucrose consumption is not known. Varenicline, a partial agonist at $\alpha4\beta2^*$, $\alpha6\beta2^*$, and $\alpha3\beta2^*$-nAChRs (*denotes the presence of other possible subunits in the receptor complex) and a full agonist at $\alpha7$ and $\alpha3\beta4^*$ subtypes [39, 40] reduces nicotine cravings and withdrawal symptoms [41] as well as in reducing alcohol consumption [42]. Varenicline displays efficacy for smoking cessation by firstly, moderately enhancing DA release in the NAc and secondly, attenuating nicotine-induced DA release by competitively blocking the nAChR binding site [43, 44]. Given the involvement of acetylcholine in appetite, it will be interesting to test the efficacy of varenicline in reducing sucrose consumption In addition, testing of other nAChR drugs may help to identify the potential nAChR subunits being targeted.

2. Materials and Methods

2.1 Drugs

5% (w/v) sucrose and 0.2% (w/v) saccharin solutions (Sigma, ST. Louis, USA) were prepared in RO-tap water. Varenicline (6,7,8,9-tetrahydro-6,10-methano-6H pyrazino[2,3-h][3]benzazepine tartrate), mecamylamine (N,2,3,3-Tetramethylbicyclo[2.2.1]heptan-2-amine hydrochloride), and (-)-cytisine ((1R,5S)-1,2,3,4,5,6-hexahydro-1,5-methano-8H-pyrido[1,2-a][1,5] diazocin-8-one) were purchased from Tocris (Bristol, UK).

2.2 Animals and Housing

Five-week-old male Wistar rats (183g ± 14g) (ARC, WA, Australia), were individually housed in ventilated dual level Plexiglas cages. The rats were acclimatized to the individual housing conditions, handling, and reverse-light cycle 5 days before the start of the experiments. All rats were housed in a climate-controlled 12-h reversed light/dark cycle (lights off at 9 a.m.) room with unlimited access to food (standard rat chow) and water. The experimental procedures followed the ARRIVE guidelines and were approved by the Ethics Committees of the Queensland University of Technology Animal Ethics Committee and the University of Queensland Animal Ethics Committee, in accordance with the European legislation (European Communities Council Directive of 24 November 1986, 86/609/EEC).

2.3 Intermittent-access two-bottle choice drinking paradigm

The intermittent access 5% sucrose two-bottle choice drinking paradigm was adapted from [45]. All fluids were presented in 300-ml graduated plastic bottles with stainless-steel drinking spouts inserted through two grommets in the front of the cage following the commencement of the dark light cycle. Two bottles were presented simultaneously: one bottle containing water; the second bottle containing 5% (w/v) sucrose. The placement of the 5% (w/v) sucrose bottle was alternated with each exposure to control for side preferences. Bottles were weighed 30 min, 2 h, and 24 h after the fluids were presented, and measurements were taken to the nearest 0.1gram. The weight of each rat was also measured to calculate the grams of sucrose intake per kilogram of body weight. On the Monday after the end of the housing acclimatization period, rats (183 ± 14 g, n = 10–12) were given access to one bottle of 5% (w/v) sucrose and one bottle of water. After 24 h, the sucrose bottle was replaced with a second water bottle that was available for the next 24 h. This pattern was repeated on Wednesdays and Fridays; All other days the rats had unlimited access to water. Drug administration began after the rats had maintained stable baseline drinking levels (20 ± 5 g/kg) of the 5% (w/v) sucrose solution for (a) short-term exposure [~4 weeks (13 drinking sessions)]; and, (b) long-term exposure [~12 weeks (37 drinking sessions)]. The mean body weight at the start of drug testing was 373 ± 26g for short-term, and 550 ± 48 g for long-term. The nAChR agonists, antagonists, and vehicle were administered as described.

In order to compare voluntary baseline sucrose consumption in animals using the intermittent-access protocol versus the continuous access protocol, a separate group (n = 10) of 5-week old wistar rats was maintained on a continuous-access 5% sucrose protocol for 4 weeks. These rats were given access to one bottle of 5% sucrose and one bottle of water 24 hours a day, seven days a week for the duration of the experiment. Sucrose and water bottles were weighed everyday (total of 56 sessions with the bottles weighed) to calculate sucrose intake and preference. Animal weights were also recorded on these days. The placement of the sucrose bottle was alternated each day to control for side preferences.

Furthermore, to determine the effect of varenicline on the consumption of a non-caloric sweetener, saccharin 0.2% (w/v), was presented to a separate group of rats (n = 10) as per the intermittent-access protocol described herein. 4 weeks from the start of saccharin consumption, rats were administered varenicline using a latin square at doses as described. Lastly, a separate group of rats on the sucrose intermittent-access protocol that were designated for autoradiography were killed by decapitation and the brains quickly removed, frozen in isopentane on dry ice and stored at -80°C. The brains were then sectioned (8 μm) at the level of the striatum using a cryostat (Leica Microsystems Inc., Deerfield, IL) set at -15 to -20°C. The sections were thaw mounted onto poly-L-lysine coated slides, dried and stored at -80°C until used for autoradiography. Rats consuming water (i.e. no sucrose) were used as control.

2.4 Treatment schedules

Wistar rats were divided into groups of 10–12. For rats on short-term drinking and also long-term drinking, Varenicline (vehicle, 0.3, 1 and 2 mg/kg) was administered to each animal using a Latin square design. Furthermore, in a group of rats (n = 8), food consumption after administration of varenicline was recorded to the nearest 0.1 gram at all time points. Subsequently, after return to baseline drinking, mecamylamine (vehicle, 0.5, 1 and 2 mg/kg), was administered as before. In a separate group of rats, (-)-cytisine (vehicle, 2 and 4 mg/kg) was administered using the Latin square design. Lastly, a separate group of rats drinking saccharin short-term was administered varenicline as before. As per Latin square design, each rat served as its own control. The doses used in this study reflect those used in the extant literature [46–51].

All drugs were dissolved in saline and administered as a subcutaneous (s.c.) injection, in a volume of 1 ml/kg, 30 min before sucrose and water bottles were presented. All drug solutions were prepared immediately before each injection.

2.5 ^{125}I-Epibatidine Autoradiography

Binding of ^{125}I-epibatidine (2200 Ci/mmol; Perkin Elmer Life Sciences, Boston, MA, USA) was done as previously reported [52]. Slides were pre-incubated at 22°C for 15 min in buffer containing 50 mM Tris, pH 7.5, 120 mM NaCl, 5 mM KCl, 2.5 mM CaCl$_2$, and 1.0 mM MgCl$_2$. They were incubated for 40 min with 0.015 nM ^{125}I-epibatidine in the presence or absence of α-conotoxin MII (α-CtxMII) (100 nM). They were then washed, dried, and exposed to Kodak MR Film with ^{125}I-microscale standards (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK) for 5–7 days. Nonspecific binding was assessed in the presence of 100 μM nicotine and was similar to the film blank.

2.6 Dopamine transporter autoradiography

Binding to the dopamine transporter (DAT) was measured using ^{125}I-RTI-121 (2200 Ci/mmol; Perkin Elmer Life Sciences, Boston, MA, USA), as previously described [53]. Thawed sections were pre-incubated twice for 15 min each at 22°C in 50 mM Tris-HCl, pH 7.4, 120 mM NaCl, and 5 mM KCl, and then incubated for 2 h in buffer with 0.025% bovine serum albumin, 1 μM fluoxetine, and 50 pM ^{125}I-RTI-121. Fluoxetine was used to block off-target binding to the serotonin transporters Sections were washed at 0°C for 4 × 15 min each in buffer and once in ice-cold water, air dried, and exposed for 2 day to Kodak MR film with ^{125}I-microscale standards (GE Healthcare). Nomifensine (100 μM) was used to define non-specific binding.

2.7 Data Analyses

The ImageQuant program from GE Healthcare was used to determine the optical density values from autoradiographic films. Background tissue values were subtracted from total tissue binding to evaluate specific binding of the radioligands. Specific binding values were then converted to fmol/mg tissue using standard curves determined from ^{125}I standards. Care was taken to ensure that sample optical density readings were within the linear range.

All statistics and curve fittings were conducted using GraphPad Prism 6 (Graph Pad Software Co., San Diego, CA, USA). Statistical comparisons were performed using unpaired t-test analysis, one-way analysis of variance (ANOVA) followed by a Newman—Keuls multiple comparisons test or two-way ANOVA followed by Bonferroni post hoc test. A value of p ≤0.05 was considered significant. All values are expressed as the mean ± SEM of the indicated number of animals, with release values for each animal representing the average of 6–15 signals from 1–2 slices.

3. Results

3.1 Varenicline reduces sucrose consumption using the intermittent-access two-bottle choice paradigm

To examine the effects of varenicline in short-term (4 week) and long-term (12 week) sucrose-consuming rats, we used the intermittent-access two-bottle choice drinking paradigm [54]. Sub-cutaneous (s.c) administration of varenicline in rats consuming sucrose short-term (Fig 1A) decreased sucrose intake [$F_{(3, 33)}$ = 3.8, $P < 0.05$]. Post hoc analysis revealed that only 2 mg/kg significantly decreased sucrose consumption. In contrast, in long-term sucrose drinking rats (Fig 1B), while varenicline decreased sucrose consumption [$F_{(3, 24)}$ = 15.24, $P < 0.0001$],

Fig 1. Long-term exposure to sucrose (12 weeks) in rats using the intermittent-access two-bottle choice paradigm increased the efficacy of varenicline. Varenicline (2 mg/kg) significantly decreased sucrose consumption (Fig 1A) after short-term (4 weeks) exposure to sucrose. Whereas, both (1 and 2 mg/kg of varenicline significantly decreased sucrose consumption (Fig 1B) following long-term (12 weeks) sucrose exposure. Varenicline (2 mg/kg) significantly decreased saccharin consumption (Fig 1C) after short-term (4 weeks) exposure to saccharin. The values are expressed as mean sucrose intake (g/kg) ± SEM (repeated-measures ANOVA followed by Newman—Keuls post hoc test). *, $P < 0.05$; **, $P < 0.01$ compared with vehicle, $n = 10$–12.

doi:10.1371/journal.pone.0150270.g001

post hoc analysis revealed both 1 and 2 mg/kg significantly decreased sucrose consumption in a dose-dependent manner compared with vehicle. Also, systemic varenicline did not affect chow consumption at any of the tested timepoints and all effective doses, both short-term and long-term. Interestingly, s.c administration of varenicline in rats consuming saccharin short-term (4 weeks) (Fig 1C) decreased saccharin intake [$F (3, 24) = 5.67$, $P < 0.05$]. Post hoc analysis revealed that only 2 mg/kg significantly decreased saccharin consumption. In all cases above, significance was observed at the 30 min timepoint, with no significance at 2hr and 24hr timepoint.

Furthermore, in contrast to the effect of varenicline on sucrose and saccharin consumption in short-term (4 weeks) sucrose-consuming animals on the intermittent-access protocol,

varenicline did not decrease sucrose consumption in animals on continuous-access to sucrose short-term (4 weeks) (Data not shown). It is to be noted that rats on intermittent-access consumed significantly more sucrose in the first 30 mins of bottle presentation than rats on continuous-access as determined by an unpaired two-tailed t-test (t = 4.025, df = 13, $P < 0.01$). Hence, all further experiments in this study utilised the intermittent-access protocol. In all cases, water consumption was not affected.

3.2 Mecamylamine, a non-competitive, non-selective nAChR antagonist reduces sucrose consumption using the intermittent-access two-bottle choice paradigm

We next examined the effect of mecamylamine, a non-competitive, non-selective nAChR antagonist, on sucrose consumption in the same intermittent-access two-bottle choice paradigm as stated above. Mecamylamine decreased sucrose consumption in short-term [F (3, 33) = 5.9, $P < 0.01$ 30min; F (3, 33) = 10.91, $P < 0.001$ 2hr] and long-term sucrose-consuming rats [F (3, 21) = 4.6, $P < 0.05$ 30 min; F (3, 21) = 10.42, $P < 0.001$ 2hr]. Post hoc analysis revealed that the dose of 2 mg/kg significantly decreased sucrose consumption at the 30 min timepoint in short-term ([Fig 2A](#)) and long-term sucrose-consuming rats ([Fig 2B](#)), and at the 2hr timepoint as well. Also, 1 mg/kg was significant short-term at the 2hr timepoint. Sucrose consumption was not affected at the 24hr timepoint for the doses tested. Water consumption was not affected at any timepoint and dose.

3.3 Cytisine reduces sucrose consumption using the intermittent-access two-bottle choice paradigm

A second group of rats were tested with (-)-cytisine, a β2-selective nAChR agonist. Cytisine significantly decreased sucrose consumption in short term [F (2, 22) = 7.18, $P < 0.01$ 30min; F (2, 22) = 6.82, $P < 0.01$ 2hr] and long-term sucrose-consuming rats [F (2,20) = 19.43, $P < 0.0001$ 30min; F (2,20) = 12.94, $P < 0.001$ 2hr]. Post hoc analysis revealed that the dose of 4 mg/kg significantly decreased sucrose consumption at the 30 min timepoint in short-term ([Fig 3A](#)) and long-term sucrose-consuming rats ([Fig 3B](#)), and at the 2hr timepoint as well. Sucrose consumption was not affected at the 24hr timepoint for the doses tested. Also, water consumption was not affected at any timepoint and dose.

3.4 Exposure to both short-term (4 week) and long-term (12 week) sucrose consumption increases α4β2* and decreases α6β2* nAChR subtype binding in the nucleus accumbens

The striatum contains two major nAChRs populations, the α4β2* and α6β2* subtypes [55]. To determine how long-term sucrose treatment modified α4β2* and α6β2* modulated subtype expression in the brain, we measured ^{125}I-epibatidine binding in the absence and presence of α-CtxMII, which blocks α6β2* nAChRs ([Fig 4A and 4B](#)). Binding determined in the presence of α-CtxMII represents that occurring at α4β2* nAChRs, while the difference between total and α4β2* nAChR binding is defined as α6β2* nAChR binding. α4(non α6)β2* nAChRs were significantly increased in the NAc of both short-term and long-term sucrose-treated animals (unpaired T-test; p = 0.024 and <0.0001, respectively). By contrast, α6β2* nAChRs ([Fig 4C and 4D](#)) were significantly decreased short-term (unpaired t-test; p = 0.028) as well as long-term (unpaired t-test; p = 0.0035) with sucrose treatment. Lastly, we also compared the binding of the dopamine transporter (DAT) by ^{125}I-RTI-121 binding to assess the modulation of

Fig 2. Mecamylamine significantly decreased sucrose intake in rats consuming sucrose short-term (4 weeks) and long-term (12 weeks) using the intermittent-access two-bottle choice paradigm. Mecamylamine (2 mg/kg) significantly decreased sucrose consumption in short-term (4 weeks) and long-term (12 weeks) sucrose exposure rats (Fig 2A and 2B). The values are expressed as mean sucrose consumed (g/kg) ± SEM (repeated-measures ANOVA followed by Newman—Keuls post hoc test). *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$ compared with vehicle, $n = 12$.

doi:10.1371/journal.pone.0150270.g002

dopamine shuttling in sucrose treated rats. There was no significant change observed short-term (4 week) and long-term (12 week) (unpaired T-test; p = 0.290 and 0.263, respectively).

4. Discussion

The present study shows that systemic administration of varenicline produced a dose-dependent reduction of sucrose consumption using the intermittent-access two-bottle choice paradigm, especially after long-term sucrose consumption. It is known that varenicline, a partial

Fig 3. Cytisine significantly decreased sucrose intake in rats consuming sucrose short-term (4 weeks) and long-term (12 weeks) using the intermittent-access two-bottle choice paradigm. Cytisine (4 mg/kg) significantly decreased sucrose consumption (Fig 3A and 3B) after the onset of drinking in short-term (4 weeks) and long-term (12 weeks) sucrose exposure rats. The values are expressed as mean sucrose consumed (g/kg) ± SEM (repeated-measures ANOVA followed by Newman—Keuls post hoc test). *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$ compared with vehicle, $n = 12$.

doi:10.1371/journal.pone.0150270.g003

Fig 4. Long-term sucrose intake (12 weeks) increases α4(nonα6)β2* nAChR and decreases α6β2* nAChR levels in rat nucleus accumbens (NAc). Quantitative analyses of α4(nonα6)β2* nAChR binding using ^{125}I-Epibatidine binding in the absence and presence of α-CtxMII show show a significant increase in α4(nonα6)β2* nAChRs (A and B) with a decrease in α6β2* nAChRs (C and D) after short-term (4 week) and long-term (12 week) sucrose exposure in the intermittent-access two-bottle choice paradigm. Dopamine transporter (DAT) as determined by ^{125}I-RTI-121 binding does not show any significant change short-term (4 week) and long-term (12 week) (E and F respectively). Each value represents the mean _ SEM of four animals per group. Significance of difference from vehicle-treated rats, ****p<0.0001, **p < 0.01, *p < 0.05.

doi:10.1371/journal.pone.0150270.g004

agonist at neuronal α4β2*, α6β2*, and α3β2*-nAChRs and a full agonist at α7 and α3β4* nAChR subtypes [39, 40], reduces nicotine cravings and withdrawal symptoms [41], as well as attenuates ethanol consumption in animal studies [42]. Furthermore, varenicline has been shown to mediate its effect at the level of the NAc [56], a key region of the limbic reward pathway in the brain. It has previously been shown that feeding to satiety increases ACh in the accumbens [57], specifically in the context of sucrose consumption [58]. Interestingly, it is the dysregulation of balance between dopamine (DA) and acetylcholine (ACh) in the limbic system, especially in the NAc that has been found to drive and maintain behaviours that perpetuate addiction to substances of abuse [59, 60]. Interestingly, varenicline did not affect sucrose consumption in the short-term continuous-access two-bottle choice paradigm suggesting that intermittent access to sucrose may contribute to neurological changes for which varenicline is effective. Future studies, however, will be necessary to ascertain this. Furthermore, it is particularly interesting that varenicline decreased not only sucrose but also saccharin consumption without affecting water intake, suggesting palatability to sweet foods as important, especially in terms of the possible involvement of the limbic system. Furthermore, following longer (12 weeks) exposure to sucrose, a lower dose of varenicline was as effective in reducing sucrose consumption as the higher dose. This differential response could be attributed to the changes observed in binding for the α4β2 containing nAChR subunits as demonstrated in this study.

We also observed that mecamylamine, a non-selective non-competitive nAChR antagonist reduced sucrose consumption. Our finding is supported by a recent study which found that mecamylamine decreased pavlovian incentive motivation for sugar [61] and operant self-administration, albeit at much higher doses [62]. Further, an *in vitro* application of mecamylamine in the NAc, decreased ghrelin-mediated accumbal DA release [63]. Cytisine, a β2 selective nAChR agonist, marketed as a smoking cessation aid Tabex in eastern European countries, also reduced sucrose consumption. An earlier report, however, investigating the effects of cytisine on ethanol consumption concluded that cytisine (3 mg/kg, s.c) did not reduce voluntary sucrose intake [64]. In addition to the potential species differences [65], there were many procedural differences between our experiments and those reported by Sajja and Rahman (2011). Most notably, Sajja and Rahman (2011) used a lower highest dose (3 mg/kg) versus 4 mg/kg in our study. However, if these factors may be attributable to the observed differences is unclear at present.

Furthermore, It is to be noted that the effect of mecamylamine and cytisine on reducing sucrose consumption for a longer time period in our study (2hr vs 30min), maybe due to the broader range of nAChR subunits targeted by mecamylamine and cytisine as compared to those targeted by varenicline [66, 67]. Furthermore, differential pharmacokinetics of mecamylamine and cytisine as compared to varenicline, may also contribute to this observed effect. These possibilities however are speculative and will need to be investigated in future studies. Also, nausea or locomotor effects may be ruled out because the doses used in our study for varenicline (0.3–2 mg/kg), mecamylamine (0.5–2 mg/kg) and cytisine (2–4 mg/kg) are similar to the doses used in previous studies, namely varenicline (0.3–3 mg/kg), mecamylamine (0.5–4 mg/kg) and cytisine (0.3–5 mg/kg) [46–51, 68–70].

The observation that not only the partial agonists varenicline and cytisine, but also the antagonist mecamylamine, reduced sucrose consumption may provide insight into the molecular mechanism whereby β2* nAChR drugs induce their effect. One possible interpretation is that it involves nAChR desensitization. Although it is quite well established that acetylcholine and nAChR agonists initially lead to nAChR activation, this is quickly followed by molecular modifications that lead to channel closing and a receptor block or desensitization [71–73]. It has been suggested that nicotine and nicotinic receptor drugs exert their overall behavioural effects via desensitization of nicotinic receptors has been suggested to underlie their mechanism of action,

at least in part, on analgesia, depression, smoking cessation and others [74–76]. If nAChR agonists exert their beneficial effects via a receptor blockade, antagonists may be more useful from a clinical standpoint. Alternatively, partial nAChR agonists, such as varenicline, may be more effective therapeutically.

In the current study, we also found that long-term sucrose exposure resulted in an increase in α4β2* and a decrease in α6β2* nAChR receptors in the NAc. Interestingly, administration of nicotine results in similar changes in the α4β2* and α6β2* nAChRs levels, and to a similar magnitude as that obtained in the present study with sucrose [77–79]. Although the mechanisms responsible for this are still not fully understood, it has been suggested that changes in α4β2* and α6β2* nAChRs contribute to nicotine re-enforcement and self-administration [80–84]. By analogy, the observed changes in nAChRs with sucrose intake may underlie the addictive properties of sucrose. It is to be noted that at present it is unclear if the observed changes in the levels of α4β2* and α6β2* nAChRs are due to the palatability of sucrose or due to increased caloric intake. Whilst varenicline had similar effects on saccharin and sucrose consumption in our study, suggesting palatability as an attractive proposition, future studies are warranted to exclude increased caloric intake as a putative causative factor for the observed changes in nAChR expression levels. This will also help to clarify the mechanism underlying the receptor changes presented in our study. In terms of sugar consumption and, more generally, food consumption, speculation remains regarding the addictive properties of these foods. Indeed, a recent review by Hebebrand and colleagues [85] discerns the nuanced difference between food addiction and the much preferred nomenclature of eating addiction. Despite these speculations, the behavioural and neural correlates in relation to sugar consumption, posit the mesolimbic pathway as an attractive target for pharmacotherapy intervention.

In conclusion, pharmacological interference with nAChRs affects sucrose consumption. Furthermore, based on the various nAChRs agonists and antagonists tested, we conclude that β2* nAChRs are involved in mediating pharmacological effects on sucrose consumption. We demonstrate that sucrose mediates an increase in α4β2* and decrease in α6β2* nAChRs in the NAc, suggesting this region as a highly plausible candidate in modulating sucrose consumption. Further studies are warranted to validate the putative role of the NAc in modulating sucrose consuming behaviour as a function of the nAChRs. Lastly, our study suggests a completely novel putative treatment strategy for reducing sugar consumption.

Supporting Information

S1 Table. Standard-chow consumption on treatment with varenicline.
(DOCX)

Acknowledgments

The authors would like to thank Carla Campus for excellent technical assistance in these studies.

Author Contributions

Conceived and designed the experiments: MS SEB JH MM MQ. Performed the experiments: MS MQ JH MM OLP VT AB. Analyzed the data: MS MQ VT AB OLP. Contributed reagents/materials/analysis tools: MS MQ SEB AB JH MM OLP. Wrote the paper: MS MQ SEB MM AB JH OLP.

References

1. WHO. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organization technical report series. 2000;894:i-xii, 1–253. Epub 2001/03/10. 11234459.

2. Te Morenga L, Mallard S, Mann J. Dietary sugars and body weight: systematic review and meta-analyses of randomised controlled trials and cohort studies. BMJ (Clinical research ed). 2013; 346:e7492. Epub 2013/01/17. doi: 10.1136/bmj.e7492 PMID: 23321486.

3. Rada P, Avena NM, Hoebel BG. Daily bingeing on sugar repeatedly releases dopamine in the accumbens shell. Neuroscience. 2005; 134(3):737–44. Epub 2005/07/01. doi: 10.1016/j.neuroscience.2005.04.043 PMID: 15987666.

4. Bassareo V, Cucca F, Frau R, Di Chiara G. Differential activation of accumbens shell and core dopamine by sucrose reinforcement with nose poking and with lever pressing. Behavioural brain research. 2015; 294:215–23. doi: 10.1016/j.bbr.2015.08.006 PMID: 26275926.

5. Bassareo V, Cucca F, Frau R, Di Chiara G. Monitoring dopamine transmission in the rat nucleus accumbens shell and core during acquisition of nose-poking for sucrose. Behavioural brain research. 2015; 287:200–6. doi: 10.1016/j.bbr.2015.03.056 PMID: 25827930.

6. Bassareo V, Cucca F, Musio P, Lecca D, Frau R, Di Chiara G. Nucleus accumbens shell and core dopamine responsiveness to sucrose in rats: role of response contingency and discriminative/conditioned cues. The European journal of neuroscience. 2015; 41(6):802–9. doi: 10.1111/ejn.12839 PMID: 25645148.

7. De Vries TJ, Shippenberg TS. Neural systems underlying opiate addiction. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2002; 22(9):3321–5.

8. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proceedings of the National Academy of Sciences of the United States of America. 1988; 85(14):5274–8. Epub 1988/07/01. PMID: 2899326; PubMed Central PMCID: PMCPMC281732.

9. Everitt BJ, Wolf ME. Psychomotor stimulant addiction: a neural systems perspective. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2002; 22(9):3312–20.

10. Hernandez L, Hoebel BG. Food reward and cocaine increase extracellular dopamine in the nucleus accumbens as measured by microdialysis. Life sciences. 1988; 42(18):1705–12. PMID: 3362036.

11. Hurd YL, Kehr J, Ungerstedt U. In vivo microdialysis as a technique to monitor drug transport: correlation of extracellular cocaine levels and dopamine overflow in the rat brain. Journal of neurochemistry. 1988; 51(4):1314–6. PMID: 3418351.

12. Picciotto MR, Corrigall WA. Neuronal systems underlying behaviors related to nicotine addiction: neural circuits and molecular genetics. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2002; 22(9):3338–41. 20026360. PMID: 11978809.

13. Pothos E, Rada P, Mark GP, Hoebel BG. Dopamine microdialysis in the nucleus accumbens during acute and chronic morphine, naloxone-precipitated withdrawal and clonidine treatment. Brain research. 1991; 566(1–2):348–50. PMID: 1814554.

14. Rada P, Pothos E, Mark GP, Hoebel BG. Microdialysis evidence that acetylcholine in the nucleus accumbens is involved in morphine withdrawal and its treatment with clonidine. Brain research. 1991; 561(2):354–6. PMID: 1802350.

15. Colantuoni C, Schwenker J, McCarthy J, Rada P, Ladenheim B, Cadet JL, et al. Excessive sugar intake alters binding to dopamine and mu-opioid receptors in the brain. Neuroreport. 2001; 12(16):3549–52.

16. Bello NT, Lucas LR, Hajnal A. Repeated sucrose access influences dopamine D2 receptor density in the striatum. Neuroreport. 2002; 13(12):1575–8. PMID: 12218708; PubMed Central PMCID: PMC1945096.

17. Spangler R, Wittkowski KM, Goddard NL, Avena NM, Hoebel BG, Leibowitz SF. Opiate-like effects of sugar on gene expression in reward areas of the rat brain. Brain research Molecular brain research. 2004; 124(2):134–42. doi: 10.1016/j.molbrainres.2004.02.013 PMID: 15135221.

18. Unterwald EM, Rubenfeld JM, Kreek MJ. Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors. Neuroreport. 1994; 5(13):1613–6. PMID: 7819531.

19. Unterwald EM, Kreek MJ, Cuntapay M. The frequency of cocaine administration impacts cocaine-induced receptor alterations. Brain research. 2001; 900(1):103–9. PMID: 11325352.

20. Alburges ME, Narang N, Wamsley JK. Alterations in the dopaminergic receptor system after chronic administration of cocaine. Synapse (New York, NY). 1993; 14(4):314–23. doi: 10.1002/syn.890140409 PMID: 8161369.

21. Moore RJ, Vinsant SL, Nader MA, Porrino LJ, Friedman DP. Effect of cocaine self-administration on dopamine D2 receptors in rhesus monkeys. Synapse (New York, NY). 1998; 30(1):88–96. doi: 10.1002/(SICI)1098-2396(199809)30:1<88::AID-SYN11>3.0.CO;2-L PMID: 9704885.

22. Georges F, Stinus L, Bloch B, Le Moine C. Chronic morphine exposure and spontaneous withdrawal are associated with modifications of dopamine receptor and neuropeptide gene expression in the rat striatum. The European journal of neuroscience. 1999; 11(2):481–90. PMID: 10051749.

23. Turchan J, Lason W, Budziszewska B, Przewlocka B. Effects of single and repeated morphine administration on the prodynorphin, proenkephalin and dopamine D2 receptor gene expression in the mouse brain. Neuropeptides. 1997; 31(1):24–8. PMID: 9574833.

24. Spangler R, Goddard NL, Avena NM, Hoebel BG, Leibowitz SF. Elevated D3 dopamine receptor mRNA in dopaminergic and dopaminoceptive regions of the rat brain in response to morphine. Brain research Molecular brain research. 2003; 111(1–2):74–83. PMID: 12654507.

25. Uhl GR, Ryan JP, Schwartz JP. Morphine alters preproenkephalin gene expression. Brain research. 1988; 459(2):391–7. PMID: 3179713.

26. Zubieta JK, Gorelick DA, Stauffer R, Ravert HT, Dannals RF, Frost JJ. Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nature medicine. 1996; 2(11):1225–9. PMID: 8898749.

27. Colantuoni C, Rada P, McCarthy J, Patten C, Avena NM, Chadeayne A, et al. Evidence that intermittent, excessive sugar intake causes endogenous opioid dependence. Obesity research. 2002; 10 (6):478–88. Epub 2002/06/11. doi: 10.1038/oby.2002.66 PMID: 12055324.

28. Rada PV, Mark GP, Taylor KM, Hoebel BG. Morphine and naloxone, i.p. or locally, affect extracellular acetylcholine in the accumbens and prefrontal cortex. Pharmacology, biochemistry, and behavior. 1996; 53(4):809–16. PMID: 8801582.

29. Rada P, Jensen K, Hoebel BG. Effects of nicotine and mecamylamine-induced withdrawal on extracellular dopamine and acetylcholine in the rat nucleus accumbens. Psychopharmacology. 2001; 157 (1):105–10. PMID: 11512050.

30. Rada P, Johnson DF, Lewis MJ, Hoebel BG. In alcohol-treated rats, naloxone decreases extracellular dopamine and increases acetylcholine in the nucleus accumbens: evidence of opioid withdrawal. Pharmacology, biochemistry, and behavior. 2004; 79(4):599–605. doi: 10.1016/j.pbb.2004.09.011 PMID: 15582668.

31. Berridge KC. From prediction error to incentive salience: mesolimbic computation of reward motivation. The European journal of neuroscience. 2012; 35(7):1124–43. Epub 2012/04/11. doi: 10.1111/j.1460-9568.2012.07990.x PMID: 22487042; PubMed Central PMCID: PMCPMC3325516.

32. Tindell AJ, Berridge KC, Zhang J, Pecina S, Aldridge JW. Ventral pallidal neurons code incentive motivation: amplification by mesolimbic sensitization and amphetamine. The European journal of neuroscience. 2005; 22(10):2617–34. Epub 2005/11/26. doi: 10.1111/j.1460-9568.2005.04411.x PMID: 16307604.

33. Wyvell CL, Berridge KC. Intra-accumbens amphetamine increases the conditioned incentive salience of sucrose reward: enhancement of reward "wanting" without enhanced "liking" or response reinforcement. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2000; 20 (21):8122–30. Epub 2000/10/26. PMID: 11050134.

34. Wyvell CL, Berridge KC. Incentive sensitization by previous amphetamine exposure: increased cue-triggered "wanting" for sucrose reward. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2001; 21(19):7831–40. Epub 2001/09/22. PMID: 11567074.

35. Kenny PJ. Common cellular and molecular mechanisms in obesity and drug addiction. Nature reviews Neuroscience. 2011; 12(11):638–51. Epub 2011/10/21. doi: 10.1038/nrn3105 PMID: 22011680.

36. Avena NM, Rada P, Hoebel BG. Evidence for sugar addiction: behavioral and neurochemical effects of intermittent, excessive sugar intake. Neuroscience and biobehavioral reviews. 2008; 32(1):20–39. Epub 2007/07/10. doi: 10.1016/j.neubiorev.2007.04.019 PMID: 17617461; PubMed Central PMCID: PMCPMC2235907.

37. Mark GP, Shabani S, Dobbs LK, Hansen ST. Cholinergic modulation of mesolimbic dopamine function and reward. Physiology & behavior. 2011; 104(1):76–81. Epub 2011/05/10. doi: 10.1016/j.physbeh.2011.04.052 PMID: 21549724.

38. McCallum SE, Taraschenko OD, Hathaway ER, Vincent MY, Glick SD. Effects of 18-methoxycoronaridine on ghrelin-induced increases in sucrose intake and accumbal dopamine overflow in female rats. Psychopharmacology. 2011; 215(2):247–56. Epub 2011/01/07. doi: 10.1007/s00213-010-2132-0 PMID: 21210086; PubMed Central PMCID: PMCPMC3790315.

39. Grady SR, Drenan RM, Breining SR, Yohannes D, Wageman CR, Fedorov NB, et al. Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptors. Neuropharmacology. 2010; 58

(7):1054–66. Epub 2010/02/02. doi: 10.1016/j.neuropharm.2010.01.013 PMID: 20114055; PubMed Central PMCID: PMCPMC2849849.

40. Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Molecular pharmacology. 2006; 70(3):801–5. Epub 2006/06/13. doi: 10.1124/mol.106.025130 PMID: 16766716.

41. Garrison GD, Dugan SE. Varenicline: a first-line treatment option for smoking cessation. Clinical therapeutics. 2009; 31(3):463–91. Epub 2009/04/28. doi: 10.1016/j.clinthera.2009.03.021 PMID: 19393839.

42. Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(30):12518–23. Epub 2007/07/13. doi: 10.1073/pnas.0705368104 PMID: 17626178; PubMed Central PMCID: PMCPMC1914040.

43. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology. 2007; 52(3):985–94. Epub 2006/12/13. doi: 10.1016/j.neuropharm.2006.10.016 PMID: 17157884.

44. Rollema H, Shrikhande A, Ward KM, Tingley FD 3rd, Coe JW, O'Neill BT, et al. Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence. British journal of pharmacology. 2010; 160 (2):334–45. Epub 2010/03/25. doi: 10.1111/j.1476-5381.2010.00682.x PMID: 20331614; PubMed Central PMCID: PMCPMC2874855.

45. Wise RA. Voluntary ethanol intake in rats following exposure to ethanol on various schedules. Psychopharmacologia. 1973; 29(3):203–10. Epub 1973/01/01. PMID: 4702273.

46. Crunelle CL, Schulz S, de Bruin K, Miller ML, van den Brink W, Booij J. Dose-dependent and sustained effects of varenicline on dopamine D2/3 receptor availability in rats. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology. 2011; 21(2):205–10. doi: 10.1016/j.euroneuro.2010.11.001 PMID: 21130610.

47. Biala G, Staniak N, Budzynska B. Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats. Naunyn-Schmiedeberg's archives of pharmacology. 2010; 381(4):361–70. doi: 10.1007/s00210-010-0498-5 PMID: 20217050.

48. Levin ED, Mead T, Rezvani AH, Rose JE, Gallivan C, Gross R. The nicotinic antagonist mecamylamine preferentially inhibits cocaine vs. food self-administration in rats. Physiology & behavior. 2000; 71 (5):565–70. PMID: 11239676.

49. Liu X, Caggiula AR, Yee SK, Nobuta H, Poland RE, Pechnick RN. Reinstatement of nicotine-seeking behavior by drug-associated stimuli after extinction in rats. Psychopharmacology. 2006; 184(3–4):417–25. doi: 10.1007/s00213-005-0134-0 PMID: 16163522; PubMed Central PMCID: PMC2810478.

50. Tutka P, Zatonski W. Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. Pharmacological reports: PR. 2006; 58(6):777–98. Epub 2007/01/16. PMID: 17220536.

51. Tutka P, Mroz T, Bednarski J, Styk A, Ognik J, Mosiewicz J, et al. Cytisine inhibits the anticonvulsant activity of phenytoin and lamotrigine in mice. Pharmacological reports: PR. 2013; 65(1):195–200. PMID: 23563038.

52. Quik M, Polonskaya Y, Gillespie A, KL G, Langston JW. Differential alterations in nicotinic receptor alpha6 and beta3 subunit messenger RNAs in monkey substantia nigra after nigrostriatal degeneration. Neuroscience. 2000; 100(1):63–72. Epub 2000/09/21. PMID: 10996459.

53. Quik M, Polonskaya Y, Kulak JM, McIntosh JM. Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2001; 21(15):5494–500. Epub 2001/07/24. PMID: 11466420.

54. Simms JA, Steensland P, Medina B, Abernathy KE, Chandler LJ, Wise R, et al. Intermittent access to 20% ethanol induces high ethanol consumption in Long-Evans and Wistar rats. Alcoholism, clinical and experimental research. 2008; 32(10):1816–23. Epub 2008/08/02. doi: 10.1111/j.1530-0277.2008.00753.x PMID: 18671810; PubMed Central PMCID: PMCPMC3151464.

55. Quik M, Wonnacott S. {alpha}6{beta}2* and {alpha}4{beta}2* Nicotinic Acetylcholine Receptors As Drug Targets for Parkinson's Disease. Pharmacol Rev. 2011; 63(4):938–66.

56. Feduccia AA, Simms JA, Mill D, Yi HY, Bartlett SE. Varenicline decreases ethanol intake and increases dopamine release via neuronal nicotinic acetylcholine receptors in the nucleus accumbens. British journal of pharmacology. 2014. Epub 2014/03/19. doi: 10.1111/bph.12690 PMID: 24628360.

57. Mark GP, Rada P, Pothos E, Hoebel BG. Effects of feeding and drinking on acetylcholine release in the nucleus accumbens, striatum, and hippocampus of freely behaving rats. Journal of neurochemistry. 1992; 58(6):2269–74. Epub 1992/06/01. PMID: 1573406.

58. Avena NM, Rada P, Moise N, Hoebel BG. Sucrose sham feeding on a binge schedule releases accumbens dopamine repeatedly and eliminates the acetylcholine satiety response. Neuroscience. 2006; 139 (3):813–20. Epub 2006/02/08. doi: 10.1016/j.neuroscience.2005.12.037 PMID: 16460879.

59. Hoebel BG, Avena NM, Rada P. Accumbens dopamine-acetylcholine balance in approach and avoidance. Current opinion in pharmacology. 2007; 7(6):617–27.

60. Aosaki T, Miura M, Suzuki T, Nishimura K, Masuda M. Acetylcholine-dopamine balance hypothesis in the striatum: an update. Geriatrics & gerontology international. 2010; 10 Suppl 1:S148–57. Epub 2010/07/16. doi: 10.1111/j.1447-0594.2010.00588.x PMID: 20590830.

61. Ostlund SB, Kosheleff AR, Maidment NT. Differential effects of systemic cholinergic receptor blockade on Pavlovian incentive motivation and goal-directed action selection. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. 2014; 39(6):1490–7. Epub 2013/12/29. doi: 10.1038/npp.2013.348 PMID: 24370780; PubMed Central PMCID: PMCPMC3988553.

62. Ford MM, Fretwell AM, Nickel JD, Mark GP, Strong MN, Yoneyama N, et al. The influence of mecamylamine on ethanol and sucrose self-administration. Neuropharmacology. 2009; 57(3):250–8. Epub 2009/06/09. doi: 10.1016/j.neuropharm.2009.05.012 PMID: 19501109; PubMed Central PMCID: PMCPMC2716427.

63. Palotai M, Bagosi Z, Jaszberenyi M, Csabafi K, Dochnal R, Manczinger M, et al. Ghrelin amplifies the nicotine-induced dopamine release in the rat striatum. Neurochemistry international. 2013; 63(4):239–43. doi: 10.1016/j.neuint.2013.06.014 PMID: 23831084.

64. Sajja RK, Rahman S. Lobeline and cytisine reduce voluntary ethanol drinking behavior in male C57BL/6J mice. Progress in neuro-psychopharmacology & biological psychiatry. 2011; 35(1):257–64. Epub 2010/11/30. doi: 10.1016/j.pnpbp.2010.11.020 PMID: 21111768.

65. Shaffer CL, Gunduz M, Ryder TF, O'Connell TN. Species differences in the biotransformation of an alpha 4 beta 2 nicotinic acetylcholine receptor partial agonist: the effects of distinct glucuronide metabolites on overall compound disposition. Drug metabolism and disposition: the biological fate of chemicals. 2010; 38(2):292–301. Epub 2009/11/17. doi: 10.1124/dmd.109.030171 PMID: 19910512.

66. Nickell JR, Grinevich VP, Siripurapu KB, Smith AM, Dwoskin LP. Potential therapeutic uses of mecamylamine and its stereoisomers. Pharmacology, biochemistry, and behavior. 2013; 108:28–43. Epub 2013/04/23. doi: 10.1016/j.pbb.2013.04.005 PMID: 23603417; PubMed Central PMCID: PMCPMC3690754.

67. Rahman S, Engleman EA, Bell RL. Nicotinic receptor modulation to treat alcohol and drug dependence. Frontiers in neuroscience. 2014; 8:426. Epub 2015/02/03. doi: 10.3389/fnins.2014.00426 PMID: 25642160; PubMed Central PMCID: PMCPMC4295535.

68. Zaniewska M, McCreary AC, Stefanski R, Przegalinski E, Filip M. Effect of varenicline on the acute and repeated locomotor responses to nicotine in rats. Synapse (New York, NY). 2008; 62(12):935–9. doi: 10.1002/syn.20564 PMID: 18798299.

69. Goutier W, Kloeze MB, McCreary AC. The effect of varenicline on the development and expression of nicotine-induced behavioral sensitization and cross-sensitization in rats. Addiction biology. 2015; 20 (2):248–58. doi: 10.1111/adb.12108 PMID: 24251901.

70. Igari M, Alexander JC, Ji Y, Qi X, Papke RL, Bruijnzeel AW. Varenicline and cytisine diminish the dysphoric-like state associated with spontaneous nicotine withdrawal in rats. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. 2014; 39(2):455–65. doi: 10.1038/npp.2013.216 PMID: 23966067; PubMed Central PMCID: PMC3870769.

71. McCarthy MJ, Zhang H, Neff NH, Hadjiconstantinou M. Desensitization of delta-opioid receptors in nucleus accumbens during nicotine withdrawal. Psychopharmacology (Berl). 2011; 213(4):735–44. Epub 2010/10/14. doi: 10.1007/s00213-010-2028-z PMID: 20941594.

72. Buccafusco JJ, Beach JW, Terry AV. Desensitization of nicotinic acetylcholine receptors as a strategy for drug development. J Pharmacol Exp Ther. 2009; 328(2):364–70. PMID: 19023041. doi: 10.1124/jpet.108.145292

73. Picciotto MR, Addy NA, Mineur YS, Brunzell DH. It is not "either/or": Activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol. 2008; 84:329–42. PMID: 18242816. doi: 10.1016/j.pneurobio.2007.12.005

74. Ortells MO, Arias HR. Neuronal networks of nicotine addiction. Int J Biochem Cell Biol. 2010; 42 (12):1931–5. Epub 2010/09/14. S1357-2725(10)00301-8 [pii] doi: 10.1016/j.biocel.2010.08.019 PMID: 20833261.

75. Zhang J, Xiao YD, Jordan KG, Hammond PS, Van Dyke KM, Mazurov AA, et al. Analgesic effects mediated by neuronal nicotinic acetylcholine receptor agonists: correlation with desensitization of alpha4-beta2* receptors. Eur J Pharm Sci. 2012; 47(5):813–23. Epub 2012/10/06. S0928-0987(12)00366-1 [pii] doi: 10.1016/j.ejps.2012.09.014 PMID: 23036283.

76. Mineur YS, Picciotto MR. Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol Sci. 2010; 31:580–6. Epub 2010/10/23. S0165-6147(10)00167-7 [pii] doi: 10.1016/j.tips.2010.09.004 PMID: 20965579.

77. Renda A, Nashmi R. Chronic nicotine pretreatment is sufficient to upregulate alpha4* nicotinic receptors and increase oral nicotine self-administration in mice. BMC neuroscience. 2014; 15:89. Epub 2014/07/21. doi: 10.1186/1471-2202-15-89 PMID: 25038610; PubMed Central PMCID: PMCPMC4133059.

78. Exley R, Clements MA, Hartung H, McIntosh JM, Franklin M, Bermudez I, et al. Striatal dopamine transmission is reduced after chronic nicotine with a decrease in alpha6-nicotinic receptor control in nucleus accumbens. The European journal of neuroscience. 2013; 38(7):3036–43. Epub 2013/07/12. doi: 10.1111/ejn.12298 PMID: 23841846.

79. Perez XA, McIntosh JM, Quik M. Long-term nicotine treatment down-regulates alpha6beta2* nicotinic receptor expression and function in nucleus accumbens. Journal of neurochemistry. 2013; 127(6):762–71. Epub 2013/09/03. doi: 10.1111/jnc.12442 PMID: 23992036; PubMed Central PMCID: PMCPMC3859710.

80. Madsen HB, Koghar HS, Pooters T, Massalas JS, Drago J, Lawrence AJ. Role of alpha4- and alpha6-containing nicotinic receptors in the acquisition and maintenance of nicotine self-administration. Addict Biol. 2014. Epub 2014/04/23. doi: 10.1111/adb.12148 PMID: 24750355.

81. Picciotto MR, Kenny PJ. Molecular mechanisms underlying behaviors related to nicotine addiction. Cold Spring Harb Perspect Med. 2013; 3(1):a012112. Epub 2012/11/13. cshperspect.a012112 [pii] doi: 10.1101/cshperspect.a012112 PMID: 23143843; PubMed Central PMCID: PMC3530035.

82. Leslie FM, Mojica CY, Reynaga DD. Nicotinic receptors in addiction pathways. Mol Pharmacol. 2013; 83(4):753–8. Epub 2012/12/19. mol.112.083659 [pii] doi: 10.1124/mol.112.083659 PMID: 23247824.

83. De Biasi M, Dani JA. Reward, addiction, withdrawal to nicotine. Annu Rev Neurosci. 2011; 34:105–30. Epub 2011/03/29. doi: 10.1146/annurev-neuro-061010-113734 PMID: 21438686; PubMed Central PMCID: PMC3137256.

84. Quik M, Perez XA, Grady SR. Role of alpha6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders. Biochem Pharmacol. 2011; 82(8):873–82. Epub 2011/06/21. S0006-2952(11)00366-2 [pii] doi: 10.1016/j.bcp.2011.06.001 PMID: 21684266; PubMed Central PMCID: PMC3264546.

85. Hebebrand J, Albayrak O, Adan R, Antel J, Dieguez C, de Jong J, et al. "Eating addiction", rather than "food addiction", better captures addictive-like eating behavior. Neuroscience and biobehavioral reviews. 2014; 47:295–306. doi: 10.1016/j.neubiorev.2014.08.016 PMID: 25205078.